Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Purple Biotech Ltd. Sponsored ADR PPBT

Healthcare  —  Biotechnology
1.49 0.01 0.68% as of 25 Sep
Market cap
$2.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)
Download Excel — free account
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
P/E ratio — — — — — 0.00 0.00 0.00 0.00 —
P/S ratio — — — — — 0.00 0.00 0.00 0.00 —
P/FCF ratio — — — — — 0.00 0.00 0.00 0.00 —
P/Operating CF — — — — — (1,089.68) (549.01) 0.00 0.00 —
P/B ratio — — — — — 165.93 282.16 0.00 0.00 —
Price to Tangible BV — — — — — 223.63 653.72 0.00 0.00 —
EV/Sales — — — — — 0.00 0.00 0.00 0.00 —
EV/EBITDA — — — — — 0.00 0.00 0.00 0.00 —
EV/Operating CF — — — — — (533.66) (154.36) 0.25 0.31 —
EV/FCF — — — — — (529.55) (154.04) 0.25 0.31 —
Quick Ratio 1.23 2.14 1.59 4.71 11.41 18.82 2.22 2.24 1.87 11.63
Current Ratio 1.27 2.23 1.63 4.71 11.41 19.14 2.34 2.57 2.01 11.70
Net Debt/EBITDA 0.35 0.79 0.70 1.43 2.67 4.45 0.92 0.85 0.62 2.04
Debt/Assets 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover 0.00 0.00 0.00 0.00 0.00 0.02 0.07 0.07 0.01 0.00
Operating CF/Net income 0.21 1.98 1.00 0.77 0.81 0.49 0.95 1.63 0.71 0.52
Capex/Depreciation (0.01) 0.00 (0.02) (1.13) (0.50) (0.66) (0.06) (2.29) (3.25) (5.00)
Interest Coverage 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
ROE (123.97%) (21.55%) (48.85%) (38.62%) (25.38%) (61.80%) (53.52%) (52.81%) (110.33%) (106.29%)
ROA (96.63%) (17.80%) (40.19%) (34.72%) (23.88%) (56.84%) (39.74%) (35.98%) (83.70%) (94.26%)
ROIC (20,189.71%) (28.20%) (73.71%) (94.27%) (62.60%) (37.70%) (100.19%) (113.22%) (596.87%) 0.00%
Return on Tangible Assets (1,179.53%) (143.51%) (318.54%) (82.04%) (41.31%) (49.68%) (122.03%) (99.29%) (301.56%) (88.89%)
Average Days of Receivables — — — 0.00 0.00 170.35 544.00 270.24 0.00 0.00
Research and Development Expense of Revenue 0.00% 0.00% 0.00% 0.00% 0.00% 675.60% 267.40% 526.80% 4,640.00% 0.00%
Selling, General and Administrative Expense of Revenue 0.00% 0.00% 0.00% 0.00% 0.00% 560.14% 607.80% 519.50% 6,397.00% 0.00%
Intangible Assets out of Total Assets 0.42 0.75 0.63 0.38 0.29 0.24 0.42 0.42 0.44 0.00
Share Based Compensation of Revenue 0.00% 0.00% 0.00% 0.00% 0.00% 246.89% 127.30% 77.30% 2,308.00% 0.00%
Graham Net Nets — — — — — 0.00 0.00 0.00 0.00 —
Graham Number — — — — — 0.00 0.00 0.00 0.00 —
Earnings Yield — — — — — (0.06%) (4.22%) (0.32%) (199.77%) —
Free Cash Flow Yield — — — — — (0.19%) (0.65%) 0.00% 0.00% —
Revenue per Share 0.00 0.00 0.00 0.00 0.00 18.63 103.09 140.85 21.28 0.00
Operating CF per Share (11.78) (87.60) (179.99) (185.12) (169.44) (239.95) (575.36) (1,194.37) (1,835.53) (2,159.31)
Capex per Share (0.01) 0.00 (0.03) (2.52) (1.31) (2.71) (1.13) (2.25) (2.77) (3.45)
Free Cash Flow per Share (11.79) (87.60) (180.02) (187.64) (170.75) (242.66) (576.49) (1,196.62) (1,838.30) (2,162.76)
Cash per Share 19.94 51.98 139.22 355.23 537.59 1,005.30 659.28 941.41 1,581.91 5,054.14
Shareholders Equity per Share 20.12 200.68 309.82 521.00 741.53 1,386.99 1,119.48 1,549.86 1,848.51 4,615.52
Interest Debt per Share 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share 20.12 200.68 309.82 521.00 741.53 1,386.99 1,119.48 1,549.86 1,848.51 4,615.52
Free Cash Flow (5.66) (14.37) (19.93) (16.96) (14.99) (13.95) (5.59) (8.50) (8.64) (6.27)
Working Capital 2.11 4.92 6.09 26.20 44.22 56.18 4.76 5.20 4.01 13.63
Capital Expenditures 0.00 — 0.00 (0.23) (0.11) (0.16) (0.01) (0.02) (0.01) (0.01)
Net Current Asset Value 1.95 4.78 5.78 25.73 43.38 55.23 4.44 4.80 2.49 13.37
EV/EBIT — — — — — 0.00 0.00 0.00 0.00 —
Capex to Sales 0.00 — 0.00 0.00 0.00 0.15 0.01 0.02 0.13 0.00
Net Profit Margin 0.00% 0.00% 0.00% 0.00% 0.00% (2,613.46%) (585.00%) (520.00%) (12,177.00%) 0.00%
Price to Operating Income — — — — — 0.00 0.00 0.00 0.00 —
Other line items
Depreciation/Fixed assets 1.64 1.50 1.28 0.93 0.83 1.32 4.68 0.19 0.14 0.13
Cash ROIC (30.05%) (34.97%) (40.39%) (21.40%) (13.49%) (10.16%) (32.57%) (48.15%) (53.68%) (22.39%)
Accounts Receivable Turnover — — — 0.00 0.00 1.08 0.90 2.24 0.00 0.00
Accounts Payable Turnover 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover — — — 0.00 0.00 0.00 — — 0.00 0.00
Average Days of Payables 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand — — — 0.00 0.00 0.00 — — 0.00 0.00
Average Receivables — — — 1.21 0.89 1.00 1.12 0.45 — 0.20
Average Payables 1.76 2.49 2.83 1.80 1.34 1.22 0.98 0.46 0.37 0.43
Average Assets 27.31 40.67 49.46 62.41 77.00 49.26 14.72 14.45 14.55 12.86
Average Common Equity 21.29 33.60 40.70 56.10 72.43 45.31 10.93 9.85 11.04 11.41

Fold the line items

Columns are period end dates